Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

NOVANTRONE

MITOXANTRONE HYDROCHLORIDE

Standard Dose
EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview NOVANTRONE is listed in Drugs@FDA under application 019297 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient MITOXANTRONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EMD SERONO Submission history Latest submission status date: 2012-03-23 00:00:00.

Structured Monograph

Clinical summary

Approval overview NOVANTRONE is listed in Drugs@FDA under application 019297 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient MITOXANTRONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - EQ 20MG BASE/10ML (EQ 2MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor EMD SERONO Submission history Latest submission status date: 2012-03-23 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
NOVANTRONE (MITOXANTRONE HYDROCHLORIDE) | Drug Monograph | MedicHelpline